Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 6,433 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Completed No phase listed Observational

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

NCT01598597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 20, 2026, 10:17 PM EDT
Not listed Not applicable Interventional

Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test

NCT04670926
View directory record Official record
Conditions
Kidney Transplant Rejection, Immunosuppression
Interventions
TruGraf, Standard of Care
Diagnostic Test · Other
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 20, 2026, 10:17 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Biomarkers to Assess Acute Kidney Injury Risk During Heat Strain

NCT05710978
View directory record Official record
Conditions
Hyperthermia, Kidney Injury, Acute
Interventions
Work Protocol
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 20, 2026, 10:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
Interventions
AZD6750, rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Terminated Phase 1Phase 2 Interventional

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT05938725
View directory record Official record
Conditions
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Interventions
KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Completed No phase listed Observational

Review of Kidney Biopsies of Dent Disease Patients

NCT02022189
View directory record Official record
Conditions
Dent Disease
Interventions
Renal Biopsy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Not applicable Interventional

Dialysis CHW Pilot

NCT05998850
View directory record Official record
Conditions
Chronic Kidney Diseases, RENAL INSUFFICIENCY, CHRONIC
Interventions
Community Health Worker Support with Resources
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Not applicable Interventional Results available

A Translational Approach to Gitelman Syndrome

NCT00822107
View directory record Official record
Conditions
Gitelman Syndrome
Interventions
Hydrochlorothiazide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Not applicable Interventional

Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3

NCT04288271
View directory record Official record
Conditions
Medication Adherence, Kidney Transplantation
Interventions
Adherence Intervention, Healthy living education intervention
Behavioral · Other
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
12 Years to 24 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

NCT01922843
View directory record Official record
Conditions
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Interventions
DP001 softgel capsules, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

NCT02876835
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
161
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 20, 2026, 10:17 PM EDT
Completed No phase listed Observational

Immune Monitoring in Sensitized Patients at Risk of Rejection

NCT03794817
View directory record Official record
Conditions
Kidney Failure
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 20, 2026, 10:17 PM EDT
Completed No phase listed Observational

Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping

NCT02161068
View directory record Official record
Conditions
ADPKD
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Phase 2 Interventional

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00354250
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
ispinesib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT01155258
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pheochromocytoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Regional Pheochromocytoma, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage III Uterine Sarcoma, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Endometrial Carcinoma, Stage IV Neuroendocrine Carcinoma of the Skin, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Thyroid Gland Medullary Carcinoma
Interventions
temsirolimus, vinorelbine ditartrate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exercise and Vascular Function in Chronic Kidney Disease

NCT02050035
View directory record Official record
Conditions
Chronic Renal Insufficiency
Interventions
Aerobic Exercise Training
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 20, 2026, 10:17 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960
View directory record Official record
Conditions
Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
Interventions
cabozantinib, atezolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions
Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
425
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 339 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

NCT03829111
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Clostridium butyricum CBM 588 Probiotic Strain, Ipilimumab, Nivolumab
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 20, 2026, 10:17 PM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT04671771
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
Interventions
InnAVasc Arteriovenous Graft (IG) surgical implant
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 90 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
22
States / cities
Phoenix, Arizona • La Mesa, California • Sarasota, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry

NCT02346435
View directory record Official record
Conditions
Kidney Neoplasm
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Recruiting Phase 3 Interventional

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

NCT05931276
View directory record Official record
Conditions
End-Stage Kidney Disease, End-Stage Renal Disease
Interventions
Metoprolol Succinate, Carvedilol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Long Beach, California • Aurora, Colorado • West Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 10:17 PM EDT
Recruiting Phase 1 Interventional

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

NCT07172958
View directory record Official record
Conditions
Rhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor
Interventions
Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 23 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 10:17 PM EDT